{
      "Rank": 185,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Mesenchymal progenitor cells low-dose group",
            "Mesenchymal progenitor cells high-dose group",
            "No mesenchymal progenitor cells"
      ],
      "ArmGroupInterventionName": [
            "Biological: Mesenchymal progenitor cells",
            "Biological: Mesenchymal progenitor cells",
            "Biological: No mesenchymal progenitor cells"
      ],
      "ArmGroupLabel": [
            "Mesenchymal progenitor cells Dosage 1",
            "Mesenchymal progenitor cells Dosage 2",
            "No mesenchymal progenitor cells"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04208646"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy"
      ],
      "BriefTitle": [
            "Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis"
      ],
      "CentralContactEMail": [
            "xck@renji.com"
      ],
      "CentralContactName": [
            "Chunde Bao, M.D. & Ph.D."
      ],
      "CentralContactPhone": [
            "021-587523545"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER"
      ],
      "CollaboratorName": [
            "RenJi Hospital",
            "Shanghai 6th People's Hospital",
            "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",
            "Second Affiliated Hospital, School of Medicine, Zhejiang University",
            "China-Japan Friendship Hospital",
            "Huashan Hospital",
            "Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University"
      ],
      "CompletionDate": [
            "January 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Knee Osteoarthritis"
      ],
      "ConditionAncestorId": [
            "D000001168",
            "D000007592",
            "D000009140",
            "D000012216"
      ],
      "ConditionAncestorTerm": [
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "All",
            "BC17"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "All Conditions",
            "Skin and Connective Tissue Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Osteoarthritis",
            "Knee Osteoarthritis"
      ],
      "ConditionBrowseLeafId": [
            "M12078",
            "M21321",
            "M3628",
            "M9773",
            "M11249",
            "M14197",
            "M5475"
      ],
      "ConditionBrowseLeafName": [
            "Osteoarthritis",
            "Osteoarthritis, Knee",
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Collagen Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000010003",
            "D000020370"
      ],
      "ConditionMeshTerm": [
            "Osteoarthritis",
            "Osteoarthritis, Knee"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Double"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator"
      ],
      "DetailedDescription": [
            "A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin\u00ae) Therapy for Knee Osteoarthritis.\n\nThis is a multicenter, randomized, double-blinded, phase II clinical trial. Subjects who are with a clinical diagnosis of knee osteoarthritis cartilage defects and will be randomly distributed 1:1:1 to different group after signing the ICF and screening tests. Each group was treated for two cycles. The patients were followed up to 48 weeks after the first treatment."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nSubjects who understand and voluntarily sign the consent form before this study\uff1b\nAccording to the diagnostic criteria (American Rheumatology Association, clinical + radiology criteria), patients with knee osteoarthritis are definitely diagnosed\uff1b\nAge: 40-75, males and females\uff1b\nThe course of knee osteoarthritis was more than 6 months and less than 10 years;\nThe subjects' WOMAC score was 24-72, and the WOMAC pain score was 7-17 (the WOMAC score at least 48 hours after discontinuation of all painkillers);\nThe Kellgren Lawrence grade (X-ray axial position of knee joint) of subjects was grade II / III;\nSubjects are generally in good condition and can walk autonomously, except for those who use wheelchairs, walking aids or crutches.\n\nExclusion Criteria:\n\nThe subject may be allergic to the main cell preparation components (B vitamins, amino acids and so on).\nThe subject received systemic and / or local treatment with autologous and / or allogeneic mesenchymal progenitor cells.\nThe subject has a BMI of over 30.\nLaboratory test (any item meets): neutrophil absolute number < 1.0 \u00d7 10^9 / L, platelet count < 50 \u00d7 10^9 / L, serum albumin < 30g / L, serum creatinine > upper limit of normal value range, total bilirubin\u3001alanine aminotransferase\u3001aspartate aminotransferase > upper limit of 2 times of normal value range.\nThe subject has diseases or symptoms may affect VAS, WOMAC and so on.\nThe subject has serious and poorly controlled concomitant diseases, such as (but not limited to) nervous system, cardiovascular, liver, kidney, gastrointestinal and endocrine diseases, which may prevent the subjects from participating in the study according to the judgment of the researchers.\nThe subject has an history malignant tumour.\nThe subject has connective tissue disease or rheumatoid arthritis\u3001chondropathy\u3001Chondrocalcinosis articularis\u3001 Hemochromatosis\u3001inflammatory arthropathy\u3001avascular necrosis of femoral head\u3001Paget's disease\u3001hemophilic arthropathy\u3001infectional arthritis\u3001Charcot' s disease\u3001villonodular synovitis or synovial chondromatosis.\nThe subject has severe generalized infectious diseases or local knee infection (including skin and intra-articular infection) in the 3 months prior to this trial.\nAccording to the researchers,the subject has disease of lower limbs which may be interfered knee evaluation, for example fibromyalgia, osphyalgia, lumbar disc protrusion and so on.\nThe subject had any other coagulation dysfunction caused by acute or chronic diseases, according to the judgment of the researchers, this coagulation dysfunction may endanger the safety of patients and / or affect the judgment of knee joint evaluation indicators.\nThe subject has received arthroscopic surgery or other open surgery related to knee joint operation in the 6 months prior to this trial.\nThe subject has received other intra-articular injections, including but not limited to hyaluronic acid, hormone, PRP, BMP (bone morphogenetic protein) , hypertonic glucose and so on for KOA in the 3 months preceding the trial.\nThe subject has received aminoglucose or chondroitin sulfate within 1 month before the treatment.\nThe subject has used dexamethasone, prednisone, hydrocortisone and other hormones orally / intravenously within 1 month before the treatment.\nThe subject has undergone knee prosthesis or a plan of knee prosthesis within the trial.\nThe subject has contraindication of MRI, included but not only: the subject installed heart pacemaker, defibrillator, heart bracket, heart valve prosthesis, metal clip after aneurysm surgery, drug infusion device implanted in vivo, any electronic device implanted in the body (nerve stimulator, bone growth stimulator) endovascular coil, strainer, ECG monitor, metal suture, shrapnel or sand of body, plate fixation and steel nail after fracture surgery, artificial cochlea, middle ear shift plant, metallic intraocular foreign body etc; the subject is a claustrophobia, critical ill patient and so on.\nThe subject tests positive for: HIV, HBV, HCV and treponema pallidum.\nThe subject has history of alcoholism, drug abuse, or mental illness in the 3 years prior to this trial.\nThe subject has participated in any other clinical trial in the 3 months prior to this trial.\nThe subject (including male subjects) has fertility, sperm donation or egg donation plans during the trial period; the female subject is pregnant, lactating or having a positive pregnancy test.\nThe subject is legally disabled by reference to the law of the people's Republic of China on the protection of disabled persons (April 2008).\nThe subject has any other unsuitable condition (such as factors reducing the follow-up compliance) to be determined by the investigator.\n\n24.The Kellgren Lawrence grade (X-ray axial position of knee joint) of any knee joint of the subjects was grade IV."
      ],
      "EnrollmentCount": [
            "108"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Mesenchymal progenitor cells Dosage 1",
            "Mesenchymal progenitor cells Dosage 2",
            "No mesenchymal progenitor cells"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use",
            "No mesenchymal progenitor cells for intra- articular use"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal progenitor cells",
            "No mesenchymal progenitor cells"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "November 4, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "November 3, 2020"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Cellular Biomedicine Group Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Beijing",
            "Hangzhou",
            "Shanghai",
            "Shanghai",
            "Shanghai",
            "Shanghai",
            "Shanghai"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [
            "Guochun Wang",
            "Shigui Yan",
            "Weiguo Wan",
            "Weiguo Wan",
            "Chengqing Yi",
            "Chunde Bao, MD",
            "Changqing Zhang",
            "Jinwu Wang"
      ],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Principal Investigator",
            "Principal Investigator",
            "Contact",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "LocationCountry": [
            "China",
            "China",
            "China",
            "China",
            "China",
            "China",
            "China"
      ],
      "LocationFacility": [
            "China-Japan Friendship Hospital",
            "The Second Affiliated hospital of Zhejiang University School of Medicine",
            "Huashan Hospital Affiliated to Fudan University",
            "Shanghai General Hospital",
            "Shanghai Jiaotong University School of Medicine, Renji Hospital",
            "Shanghai Sixth People's Hospital",
            "Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Not yet recruiting"
      ],
      "LocationZip": [
            "100029",
            "310009",
            "200040",
            "200080",
            "200127",
            "200233"
      ],
      "MaximumAge": [
            "75 Years"
      ],
      "MinimumAge": [
            "40 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin\u00ae) for the Treatment of Knee Osteoarthritis"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Cellular Biomedicine Group Ltd."
      ],
      "OrgStudyId": [
            "CBM-ALAM.1-01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [
            "Levels of cartilage metabolism and inflammatory biomarkers in serum and urine will be tested at 0\u30014\u30018\u300112\u300124\u300136\u300148 weeks"
      ],
      "OtherOutcomeMeasure": [
            "Metabolic index detection"
      ],
      "OtherOutcomeTimeFrame": [
            "0\u30014\u30018\u300112\u300124\u300136\u300148 weeks"
      ],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Shanghai Jiaotong University School of Medicine, Renji Hospital",
            "Shanghai 6th People's Hospital",
            "China-Japan Friendship Hospital",
            "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",
            "Second Affiliated Hospital, School of Medicine, Zhejiang University",
            "Huashan Hospital",
            "Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University"
      ],
      "OverallOfficialName": [
            "Chunde Bao",
            "Changqing Zhang",
            "Guochun Wang",
            "Chengqing Yi",
            "Shigui Yan",
            "Weiguo Wan",
            "Jinwu Wang"
      ],
      "OverallOfficialRole": [
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2021"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points\uff1b96 points mean a worse outcome,will be tested at 24 weeks after the first injection"
      ],
      "PrimaryOutcomeMeasure": [
            "WOMAC Score"
      ],
      "PrimaryOutcomeTimeFrame": [
            "24 weeks"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 24\u300148 weeks after the first injection",
            "The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points\uff1b96 points mean a worse outcome, will be tested at 4\u30018\u300112\u300136\u300148 weeks after the first injection",
            "Visual Analogue Scale/Score\uff1b0-10 points\uff1b10 points mean a worse outcome,will be tested at 4\u30018\u300112\u300124\u300136\u300148 weeks after the first injection",
            "The Medical Outcomes Study 36-Item Short-Form Health Survey;0-100 points\uff1b100 points mean a better outcome, will be tested at 4\u30018\u300112\u300124\u300136\u300148 weeks after the first injection",
            "AE and SAE, will be assessed at 0d\u30011\u30013\u30014\u30018\u300112\u300124\u300125\u300127\u300128\u300136\u300148 weeks",
            "Vital signs, physical examination, clinical laboratory tests:infectious disease check, blood coagulation test , blood check, urine check, blood biochemical test, immunological examination, tumor screening ,will be tested at 0d\u30011\u30013\u30014\u30018\u300112\u300124\u300125\u300127\u300128\u300136\u300148 weeks"
      ],
      "SecondaryOutcomeMeasure": [
            "MRI quantitative analysis of articular cartilage",
            "WOMAC Score",
            "VAS Score",
            "SF-36",
            "Adverse Events and Serious Adverse Events",
            "Changes of laboratory test indexes and vital signs"
      ],
      "SecondaryOutcomeTimeFrame": [
            "24 weeks,48 weeks",
            "4\u30018\u300112\u300136\u300148 weeks",
            "4\u30018\u300112\u300124\u300136\u300148 weeks",
            "4\u30018\u300112\u300124\u300136\u300148 weeks",
            "0d\u30011\u30013\u30014\u30018\u300112\u300124\u300125\u300127\u300128\u300136\u300148 weeks",
            "0d\u30011\u30013\u30014\u30018\u300112\u300124\u300125\u300127\u300128\u300136\u300148 weeks"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 16, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "November 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "December 23, 2019"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "December 17, 2019"
      ],
      "StudyFirstSubmitQCDate": [
            "December 19, 2019"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}